Poly(ADP-ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells

Cancer Research

Volumn 71, Issue 14, 2011, Pages 4944-4954

  Huehls, Amelia M ^a   Wagner, Jill M ^a   Huntoon, Catherine J ^a   Geng, Liyi ^a   Erlichman, Charles ^a   Patel, Anand G ^a   Kaufmann, Scott H ^a   Karnitz, Larry M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BASE EXCISION REPAIR PROTEIN; CARBOPLATIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; MELPHALAN; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUCLEIC ACID BINDING PROTEIN; OLAPARIB; OXALIPLATIN; SMALL INTERFERING RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VELIPARIB; XRCC1 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; MONOTHERAPY; OVARY CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BENZIMIDAZOLES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA REPAIR; DNA-BINDING PROTEINS; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; FLOXURIDINE; FLUOROURACIL; HUMANS; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 79960418121     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0814     Document Type: Article

References (47)

1. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8. (Pubitemid 37328853)
2. Power DG, Kemeny NE. The role of floxuridine in metastatic liver disease. Mol Cancer Ther 2009;8:1015-25.
3. Ardalan B, Lima M. A phase II trial of FUdR in patients with advanced pancreatic cancer. J Cancer Res Clin Oncol 2004;130:561-6. (Pubitemid 39371326)
4. Vokes EE, Raschko JW, Vogelzang NJ, Warfield EE, Ratain MJ, Doroshow JH, et al. Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study. Cancer Chemother Pharmacol 1991;28:69-73.
5. Damascelli B, Marchiano A, Frigerio LF, Salvetti M, Spreafico C, Garbagnati F, et al. Flexibility and efficacy of automatic continuous fluorodeoxyuridine infusion in metastases from a renal cell carcinoma. Cancer 1991;68:995-8.
6. Leichman L, Silberman H, Leichman CG, Spears CP, Ray M, Muggia FM, et al. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol 1992;10:1933-42. (Pubitemid 23064206)
7. Newman E, Potmesil M, Ryan T, Marcus S, Hiotis S, Yee H, et al. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study. Semin Oncol 2005;32:S97-100.
8. Muggia FM, Liu PY, Alberts DS, Wallace DL, O'Toole RV, Terada KY, et al. Intraperitoneal mitoxantrone or floxuridine: effects on time-tofailure and survival in patients with minimal residual ovarian cancer after second-look laparotomy-a randomized phase II study by the Southwest Oncology Group. Gynecol Oncol 1996;61:395-402.
9. Brenner B, Shah MA, Karpeh MS, Gonen M, Brennan MF, Coit DG, et al. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol 2006;17:1404-11. (Pubitemid 44403435)
10. Israel VK, Jiang C, Muggia FM, Tulpule A, Jeffers S, Leichman L, et al. Intraperitoneal 5-fluoro-20-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol 1995;37:32-8.
11. Muggia FM, Chan KK, Russell C, Colombo N, Speyer JL, Sehgal K, et al. Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2′- deoxyuridine. Cancer Chemother Pharmacol 1991;28:241-50.
12. Wyatt MD, WilsonDMIII. Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 2009;66:788-99.
13. Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 2008;27:6522-37.
14. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003;22:9063-74. (Pubitemid 38121707)
15. Liu X, Matsuda A, Plunkett W. Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2′-Ccyano- 2′-deoxy-1-beta-D- arabino-pentofuranosylcytosine. Mol Cancer Ther 2008;7:133-42.
16. Liu A, Yoshioka K, Salerno V, Hsieh P. The mismatch repair-mediated cell cycle checkpoint response to fluorodeoxyuridine. J Cell Biochem 2008;105:245-54.
17. Jardim MJ, Wang Q, Furumai R, Wakeman T, Goodman BK, Wang XF. Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells. Mol Biol Cell 2009;20:3801-9.
18. Wilsker D, Bunz F. Loss of ataxia telangiectasia mutated- and Rad3- related function potentiates the effects of chemotherapeutic drugs on cancer cell survival. Mol Cancer Ther 2007;6:1406-13. (Pubitemid 46712004)
19. Parsels LA, Parsels JD, Tai DC, Coughlin DJ, Maybaum J. 5-fluoro-2′- deoxyuridine-induced cdc25A accumulation correlates with premature mitotic entry and clonogenic death in human colon cancer cells. Cancer Res 2004;64:6588-94. (Pubitemid 39297918)
20. Robinson HM, Jones R, Walker M, Zachos G, Brown R, Cassidy J, et al. Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 2006;25:5359-69. (Pubitemid 44330279)
21. Xiao Z, Xue J, Sowin TJ, Zhang H. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther 2006; 5:1935-43. (Pubitemid 44336564)
22. Xiao Z, Xue J, Sowin TJ, Rosenberg SH, Zhang H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 2004;24:1403-11.
23. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 2008;9:616-27. (Pubitemid 352032926)
24. Matuo R, Sousa FG, Escargueil AE, Grivicich I, Garcia-Santos D, Chies JA, et al. 5-fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line. J Appl Toxicol 2009;29:308-16.
25. El-Awady RA, Saleh EM, Dahm-Daphi J. Targeting DNA doublestrand break repair: is it the right way for sensitizing cells to 5- fluorouracil?Anticancer Drugs 2010;21:277-87.
26. Kurz EU, Lees-Miller SP. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair 2004;3:889-900. (Pubitemid 38997931)
27. Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair in mammalian cells: base excision repair: the long and short of it. Cell Mol Life Sci 2009;66:981-93.
28. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010;10:293-301.
29. Chien J, Narita K, Rattan R, Giri S, Shridhar R, Staub J, et al. A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation. Oncogene 2008;27:7223-34.
30. Wang Y, Qin J. MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. Proc Natl Acad Sci U S A 2003;100:15387-92. (Pubitemid 38020999)
31. Casper AM, Durkin SG, Arlt MF, Glover TW. Chromosomal instability at common fragile sites in Seckel syndrome. Am J Hum Genet 2004;75:654-60. (Pubitemid 39244779)
32. Luo H, Chan DW, Yang T, Rodriguez M, Chen BP, Leng M, et al. A new XRCC1-containing complex and its role in cellular survival of methyl methanesulfonate treatment. Mol Cell Biol 2004;24: 8356-65. (Pubitemid 39245058)
33. Kameoka M, Nukuzuma S, Itaya A, Tanaka Y, Ota K, Ikuta K, et al. RNA interference directed against Poly(ADP-Ribose) polymerase 1 efficiently suppresses human immunodeficiency virus type 1 replication in human cells. J Virol 2004;78:8931-4. (Pubitemid 39025160)
34. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8. (Pubitemid 32494397)
35. Huntoon CJ, Nye MD, Geng L, Peterson KL, Flatten KS, Haluska P, et al. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway. Cancer Res 2010;70:8642-50.
36. Wagner JM, Karnitz LM. Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Mol Pharmacol 2009;76:208-14.
37. Morgan MA, Parsels LA, Parsels JD, Lawrence TS, Maybaum J. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 2006;5:1983-8. (Pubitemid 44435305)
38. Kinner A, Wu W, Staudt C, Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 2008;36:5678-94.
39. Madoc-Jones H, Bruce WR. On the mechanism of the lethal action of 5-fluorouracil on mouse L cells. Cancer Res 1968;28:1976-81.
40. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
41. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009;27:2705-11.
42. Corfield VA, Hay RJ. Effects of cystine or glutamine restriction on human diploid fibroblasts in culture. In Vitro 1978;14:787-94. (Pubitemid 9028554)
43. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005;65:6394-400. (Pubitemid 40994427)
44. http://clinicaltrials.gov/ct2/results?term=abt-888+temozolomide.
45. Ganzinelli M, Carrassa L, Crippa F, Tavecchio M, Broggini M, Damia G. Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clin Cancer Res 2008;14:5131-41.
46. McNeill DR, Lam W, DeWeese TL, Cheng YC, Wilson DM III. Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol Cancer Res 2009;7: 897-906.
47. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA: Cancer J Clin 2009;60:277-300.